Using Femara to Prevent Breast Cancer Recurrence

According to the cancer survey, more than 215,000 women were identified as patients with breast cancer each year. In short, patients with breast cancer not only surgical treatment given, must sometimes undergo chemotherapy or radiotherapy to completely remove the tumor. Then the women decide with their doctor or not adjuvant therapy is a treatment to help prevent the cancer coming back. You might be interested to read the cancer and how to prepare for the influence of breast cancer.

When a woman has breast cancer makes people come back or spread to other parts of the body, the woman would be more likely to die of the disease. Women whose breast cancer is found in nearby lymph nodes on the medical diagnosis and chemotherapy after surgery are considered at high risk of recurrence of breast cancer.

The postmenopausal women with early breast cancer hormone sensitive have a new option as the first hormonal treatment after surgery. The U. S. Food and Drug Administration recently approved Femara (letrozole tablets) December 28, 2005 for this service. This acceptance is based on an average of several years of treatment. The investigation is under way to find long-term safety and efficacy of Femara. Already a leader in the treatment of breast cancer, Femara is the only drug in a band called aromatase inhibitors approved for use both immediately after surgery and after five years of tamoxifen. Femara FDA priority review, a distinction reserved for drugs that could provide a significant advance on the elements on the market.

A panel of the American Society of Clinical Oncology, the group of oncologists large, aromatase inhibitors Femara as recommended, the best adjuvant treatment for these women.

"One of the major problems that affect the state women fully medicated early breast cancer is that their cancer will return. With Femara, we have the opportunity to face fear early can help, even in patients in whom we have concluded that high risk of recurrence, "said Matthew Ellis, MD, PhD, FRCP, Director of Cancer at Washington University in St. Louis.

In the clinical analysis of the major post-surgical treatment of breast cancer, the researchers compared the effectiveness of Femara and tamoxifen, another drug prescribed after surgery. An analysis conducted after 26 months showed that Femara reduced the risk of breast cancer returning by 21% compared to the reduction provided by tamoxifen. Patients treated with Femara showed a 27% reduction in the risk of cancer spreading to other parts of the body.

In this study, women at increased risk of relapse experienced the greatest benefit of Femara. Femara reduced the risk by 29% in women with breast cancer had already spread to lymph nodes at diagnosis and 30% in women with chemotherapy. The results also indicate that in these high-risk women, Femara potential risk of spread of cancer to other parts of the body by 33% and 31%, or decreased.

The study mentioned above, we can see that the treatment Femara no adverse effects on patients can induce. Side effects like joint pain, weight gain, and so on are really scary.

Last but not least, the return of breast cancer can be prevented if Femara is fully utilized by your doctor. Maybe we just need more time to trust this new product.